SMA Outpatient Daytona

SMA Outpatient Daytona is a SAMHSA-registered addiction-treatment facility located at Daytona Beach, FL. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at SMA Outpatient Daytona

SMA Outpatient Daytona is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care SMA Outpatient Daytona provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Payment and insurance posture: SMA Outpatient Daytona accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Young adults, Clients with co-occurring mental and substance use disorders. Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission due-diligence for SMA Outpatient Daytona: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via FL behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether SMA Outpatient Daytona offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.